SURMOUNT-2 · 2023

SURMOUNT-2 — Tirzepatide in T2D

Tirzepatide in adults with overweight/obesity AND T2D.

Headline finding

14.7% body-weight reduction at 72 weeks at 15 mg.

Population
938 adults with T2D and BMI ≥27
Duration
72 weeks
Citation
Garvey WT et al., Lancet 2023

Summary is editorial; consult the original publication for the full methodology and statistical detail.

Get matched

Want a real recommendation?

Five minutes. Free. No pressure.

Start my consultation